Neuronetics (STIM) Set to Announce Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIMGet Rating) will issue its quarterly earnings data before the market opens on Tuesday, November 8th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Neuronetics Price Performance

Shares of STIM opened at $3.58 on Friday. The company has a current ratio of 5.02, a quick ratio of 4.64 and a debt-to-equity ratio of 0.46. Neuronetics has a 1 year low of $1.98 and a 1 year high of $5.91. The stock has a market cap of $96.73 million, a P/E ratio of -2.56 and a beta of 1.99. The stock’s 50-day moving average price is $3.10 and its two-hundred day moving average price is $3.27.

Hedge Funds Weigh In On Neuronetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STIM. Envestnet Asset Management Inc. boosted its holdings in Neuronetics by 131.7% during the first quarter. Envestnet Asset Management Inc. now owns 80,811 shares of the company’s stock worth $245,000 after buying an additional 45,928 shares during the last quarter. Blair William & Co. IL lifted its holdings in shares of Neuronetics by 12.2% during the 1st quarter. Blair William & Co. IL now owns 193,723 shares of the company’s stock valued at $587,000 after purchasing an additional 21,137 shares in the last quarter. Gabelli Funds LLC lifted its holdings in shares of Neuronetics by 3.3% during the 1st quarter. Gabelli Funds LLC now owns 254,077 shares of the company’s stock valued at $770,000 after purchasing an additional 8,200 shares in the last quarter. Nantahala Capital Management LLC bought a new position in shares of Neuronetics during the 1st quarter valued at about $2,667,000. Finally, Renaissance Technologies LLC bought a new position in shares of Neuronetics during the 1st quarter valued at about $564,000. Institutional investors own 64.61% of the company’s stock.

About Neuronetics

(Get Rating)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Read More

Earnings History for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.